As a result of a problem with the manufacturing process of Insuman, the production and release of all batches of Insuman Basal, Comb and Rapid (cartridges and pre-filled pens) has been reduced. Temporary supply disruptions are expected in Bulgaria, Czech Republic, Hungary, Norway and Poland while the issue is being addressed.
Insuman is a range of insulin-containing solutions and suspensions for injection.
Healthcare Professionals in countries affected will be informed of the shortage by the company. In the instance of shortage, healthcare professionals are being advised to prescribe an alternative human insulin, taking into account local and national guidance. Healthcare Professionals should ensure that patients monitor their blood glucose closely during the switch to a different human insulin.
The shortage will not affect Insuman vials, Insuman Implantable vials, Infusat vials and Infusat cartridges.
See theEuropean Medicines Agency (EMA) information sheet (PDF, 74KB) for more information.